F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) to participants with prostate cancer that has come back. Diagnostic procedures, such as fluorine F 18 DCFPyL PET/CT, may help find and diagnose prostate cancer and find out how far the disease has spread.

Official Title

18F-DCFPyL PET/CT in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-Contributory CT Scans

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Biopsy proven prostate adenocarcinoma - Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy) - Post radical prostatectomy (RP) - American Urological Association (AUA) recommendation - PSA greater than 0.2 ng/mL measured after at least 6 weeks from radical prostatectomy - Confirmatory persistent PSA greater than 0.2 ng/mL (total of two PSA measurements greater than 0.2 ng/mL) - Post-radiation therapy - American Society for Radiation Oncology (ASTRO) - Phoenix consensus definition - A rise of PSA measurement of 2 or more ng/mL over the nadir - Able to provide written consent - Karnofsky performance status of > 50 (or Eastern Cooperative Oncology Group [ECOG] / World Health Organization [WHO] equivalent)
Exclusion Criteria:
  1. - Unable to provide informed consent - Inability to lie still for the entire imaging time - Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) - Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance


Andrei Iagaru
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)

Contact us to find out if this trial is right for you.


Pranav Hegde